FDA approves drug that can spare bladder cancer patients from surgery

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells. Sponsored Content A Deep-Dive into Specialty Pharma Presented by PurpleLab A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed "orphan" diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS. Learn More. Only 4 Days Left to Join Top Healthcare Investors & Startups at INVEST 2024! Join elite investors, innovative startups & top healthcare executives for panel discussions on the hottest industry topics, pitch contests & networking galore in Chicago next month! Connect with the best in healthcare at this unique boutique networking event May 21 & 22 in Chicago. Hurry, you can still save $100. Don't miss out – offer ends this Saturday!

Featured News

Why Headspace Is Launching Direct-to-Consumer Services Headspace is going toe-to-toe with the likes of Talkspace and BetterHelp by bringing its mental health services directly to consumers — starting with text-based mental health coaching. Collaboration Now: Maximizing AI's Potential in the Industry it Matters Most No passing fad, AI in healthcare is here, and it's already improving the lives of patients, healthcare workers, and researchers. How can we make a good thing even better?

Resources

MedCity Debunked: Change Healthcare Cybersecurity Attack, 23andMe Relevance and Startup Tips In this month's episode, we talk about the massive cyberattack at Change Healthcare that brought the healthcare payment processing clearinghouse to its knees. How were providers, patients, pharmacies, and health systems affected? We also talk about 23AndMe and its relevance in the marketplace. Finally, as a journalist and investor, we offer advice to startups on what is a turn-off for us.  Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe